RAFA To Add Major Component to the Tashkent Pharma Park
RAFA To Add Major Component to the Tashkent Pharma Park
Nicosia, Cyprus, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and the Czech company "Block" signed an agreement on the implementation of the construction of a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park in Uzbekistan. The new partner of the promising project is the multinational engineering group BLOCK with a unique specialization and experience in the field of healthcare and pharmacology. The interests of Rafarma in this agreement will be represented by the company RAFA Therapeutics Uzbekistan.
塞浦路斯尼科西亞,2021年12月17日(環球通訊社)拉法瑪製藥公司場外交易:(RAFA)與捷克“Block”公司簽署了在烏茲別克斯坦塔什干醫藥園區境內建設科學和醫藥綜合體的實施協議。這個前景看好的項目的新合作伙伴是在醫療保健和藥理學領域擁有獨特專業化和經驗的跨國工程集團Block。Rafarma在這項協議中的利益將由烏茲別克斯坦Rafa治療公司代表。
In accordance with the agreement, Block will undertake the design of the future complex, including a system of clean laboratory rooms with all the necessary equipment within the framework of the project. The centerpiece will be a project for a plant to produce drugs from human blood plasma with a potential processing capacity of more than 1 million liters of plasma per year and an investment volume of more than US $50 million dollars. Its launch will allow Uzbekistan to become one of the 10 countries in the world with the largest fractionation plants for the processing of blood components.
根據協議,布洛克將承擔未來綜合體的設計,包括一個乾淨的實驗室系統,以及項目框架內所有必要的設備。該項目的核心將是一個從人體血漿中生產藥物的工廠項目,該項目的潛在處理能力為每年100多萬升血漿,投資額超過5000萬美元。它的推出將使烏茲別克斯坦成為世界上擁有最大的血液成分分餾工廠的10個國家之一。
We plan to complete the design work in April 2022 and begin construction of the first phase of the plant in the summer of 2022.
我們計劃在2022年4月完成設計工作,並在2022年夏天開始建設一期工廠。
This latest development is part of Rafarma Pharmaceuticals' previous announcement to build a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park by the end of 2026. At the first stage, it is planned to organize the production of cancer drugs and drugs from human donor blood plasma. At the second stage, a complex will be built for the production of drugs based on antibodies (-MABs) and radiopharmaceuticals used for the diagnosis and treatment of various types of cancer. In addition to modern high-tech production lines, the project provides for the creation of a network of laboratories for the collection of blood plasma, the total investment is US $85 million dollars. Experts recognize these construction plans as the largest innovative project of the industrial zone of the Tashkent Pharma Park pharmaceutical cluster.
這一最新進展是拉法瑪製藥公司此前宣佈的在2026年底之前在塔什干製藥園區境內建造一個科學和製藥綜合體的一部分。在第一階段,計劃組織從人類捐贈者血漿中生產抗癌藥物和藥物。在第二階段,將建造一個綜合體,用於生產基於抗體(-MAbs)和用於診斷和治療各種癌症的放射性藥物的藥物。除了現代化的高科技生產線外,該項目還將建立一個血漿採集實驗室網絡,總投資為8500萬美元。專家認為,這些建設計劃是塔什干醫藥園區醫藥集羣工業區最大的創新項目。
Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate," or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
前瞻性陳述:本新聞稿包含1934年證券交易法第21E節所指的“前瞻性陳述”。除本文包含的歷史事項外,本新聞稿中的陳述均為前瞻性陳述。在不限制前述一般性的情況下,諸如“可能”、“將”、“到”、“計劃”、“預期”、“相信”、“預期”、“打算”、“可能”、“將”、“估計”或“繼續”等詞語或其負面的其他變體或類似術語旨在識別前瞻性陳述。前瞻性陳述涉及已知和未知的風險、不確定因素和其他因素,這些風險、不確定性和其他因素可能導致我們的實際結果、表現或成就與前瞻性陳述明示或暗示的任何未來結果、表現或成就大不相同。此外,前瞻性陳述僅代表我們管理層截至本文發佈之日的信念和假設。有關可能導致實際結果與這些前瞻性陳述大不相同的因素的更多信息,請參閲公司向場外交易市場提交的文件。除非法律要求,否則我們沒有義務公開更新這些前瞻性陳述,或更新實際結果可能與這些前瞻性陳述中預期的結果大不相同的原因,即使未來有新的信息。
For more information contact:
RAFARMA
(307) 429-2029
如需更多信息,請聯繫:
拉法爾馬
(307) 429-2029